Federal Circuit Affirms Invalidity of Alzheon’s Alzheimer’s Drug Patent in PTAB Appeal
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Risen (Suzhou) Pharma Tech Co., Ltd. v. Alzheon, Inc. |
| Numéro de dossier | 22-2232 (Fed. Cir.) |
| Tribunal | Circuit fédéral, appel de la PTAB |
| Durée | Sept 2022 – March 2024 1 year 6 months |
| Résultat | Patent Unpatentable / Invalidated |
| Brevets en cause | |
| Domaine technologique | Isotope-enriched 3-APS derivatives |
Aperçu du dossier
Les parties
⚖️ Auteur de la pétition
China-based pharmaceutical technology company with operations relevant to active pharmaceutical ingredient synthesis and drug development.
🛡️ Patent Owner
U.S.-based clinical-stage biopharmaceutical company focused on Alzheimer’s disease therapeutics, leveraging isotope-enriched 3-APS formulations.
Le brevet en cause
This landmark case involved U.S. Patent No. 10,472,323 B2, covering isotope-enriched 3-amino-1-propanesulfonic acid (3-APS) derivatives — a compound class central to Alzheimer’s disease drug development. Isotope enrichment, particularly deuterium substitution, is a recognized strategy in pharmaceutical development to modify a drug’s metabolic profile, potentially improving efficacy or reducing side effects.
- • US10,472,323 B2 — Isotope-enriched 3-amino-1-propanesulfonic acid derivatives
Developing a new drug compound?
Check if your pharmaceutical derivative might infringe existing patents before clinical trials.
Le verdict et l'analyse juridique
Résultat
The Federal Circuit **affirmed** the finding of **unpatentability** of U.S. Patent No. 10,472,323 B2. No damages were at issue, consistent with the nature of an invalidity/cancellation proceeding rather than an infringement action. The affirmance extinguishes Alzheon’s patent rights in the challenged claims, rendering the patent unenforceable as a matter of law.
Principales questions juridiques
The Federal Circuit’s affirmance validates the underlying invalidity/cancellation action, which most commonly rests on **obviousness under 35 U.S.C. § 103**. For isotope-enriched pharmaceutical derivatives, the central validity question is whether deuterium substitution of a known compound — here, 3-APS (tramiprosate) — would have been obvious to a person of ordinary skill in the art (POSITA) given prior art disclosing both the parent compound and known deuterium-labeling techniques.
The decision reinforces the **Federal Circuit’s demanding patentability standard** for isotopically labeled drug derivatives. Patent applicants in the deuterium drug space must demonstrate more than structural novelty; they must show unexpected results, distinct pharmacological profiles, or non-obvious technical advantages over the parent compound and known labeling art.
Analyse de la liberté d'exploitation (FTO)
Ce cas met en évidence les risques critiques liés à la propriété intellectuelle dans le développement de composés pharmaceutiques. Choisissez la prochaine étape :
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- Consulter les brevets relatifs aux composés dans ce domaine technologique
- See which companies are most active in deuterium drug patents
- Understand obviousness trends for isotopically labeled compounds
🔍 Check My Compound’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical compound or derivative.
- Input your compound structure or technical features
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
High Obviousness Risk
Isotope-enriched known compounds
Related Art Exist
On parent compound and labeling techniques
IPR Effectiveness
Demonstrated for derivative patents
✅ Points clés à retenir
Federal Circuit affirmed PTAB’s unpatentability finding for isotope-enriched pharmaceutical derivative (US10,472,323 B2).
Rechercher la jurisprudence connexe →Deuterium substitution of known compounds faces heightened obviousness scrutiny absent unexpected results evidence.
Explorer les précédents en matière d'évidence →IPR remains a powerful and strategically efficient invalidity mechanism in pharmaceutical patent disputes.
Analyser les taux de réussite des droits de propriété intellectuelle →Foire aux questions
U.S. Patent No. 10,472,323 B2, covering isotope-enriched 3-amino-1-propanesulfonic acid derivatives and their pharmaceutical uses (Application No. US15/476,255).
The Federal Circuit affirmed an invalidity/cancellation determination, consistent with an IPR proceeding where patentability — most likely on obviousness grounds — was successfully challenged by Risen (Suzhou) Pharma Tech Co., Ltd.
The decision reinforces that isotopic labeling of known pharmaceutical compounds requires demonstrated non-obvious advantages to sustain patentability, raising the evidentiary bar for similar patents across the CNS and broader pharmaceutical sectors.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- United States Court of Appeals for the Federal Circuit — Case No. 22-2232
- USPTO Patent Center — US10,472,323 B2
- PACER — Case No. 22-2232
- Cornell Legal Information Institute — 35 U.S.C. § 103
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.